-
The world's first
Time of Update: 2022-08-15
status Anhan Technology is an internationally leading high-tech enterprise focusing on the R&D, production and operation of innovative medical devices in the field of digestive tract health.
-
Preoperative immunotherapy plus chemotherapy improves outcomes in lung cancer patients
Time of Update: 2022-05-14
The addition of the immunotherapy drug nivolumab to preoperative (neoadjuvant) chemotherapy in patients with operable non-small cell lung cancer (NSCLC) reduces the risk of cancer recurrence or death by more than three-fold, results from the CheckMate-816 phase III trial show one .
-
The pace of approval and marketing of domestic innovative drugs will continue to accelerate, bursting out more new vitality
Time of Update: 2022-05-08
The industry predicts that 19 blockbuster new drugs will be approved in 2022, and two of the 19 innovative drugs will be independently developed by domestic pharmaceutical companies .
-
Transwin Group Presents Preliminary Data on Safety, Tolerability and Antitumor Activity of TST001 Monotherapy in China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
Time of Update: 2022-04-30
SUZHOU, March 10, 2022 /PRNewswire/ -- Chuangsheng Group, a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biopharmaceutical discovery, R&D, process development and production, announced that at the 2022 International Gastric Cancer Congress (IGCC) ) in the form of a poster to show the safety, tolerability and preliminary efficacy data of TST001 monotherapy in the Phase I clinical trial in China and its antitumor activity against gastric and pancreatic cancer .
-
Clinical CRO "Clash of Kings
Time of Update: 2022-04-27
It was after this stage that Tigermed and WuXi AppTec, two listed companies rooted in clinical CROs, ushered in a high performance growth that they had never had before.
-
The first KRAS inhibitor license out
Time of Update: 2022-01-03
According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.
-
The pharmaceutical sector ushered in a good layout opportunity, and the industry continues to focus on these segments
Time of Update: 2021-10-20
At the same time, the three quarterly reports are about to usher in a concentrated disclosure period, and it is recommended to pay attention to the targets of the rapid growth of CXO industry performance .
-
The sixth batch of countries organize the public procurement of drugs (insulin special) related companies and product lists
Time of Update: 2021-09-18
622, Jumen Road, Huangpu District, Shanghai Phone: 021-31773244; 31773255; 31773266 Attachment: The sixth batch of national organization of centralized drug procurement (insulin special) related companies and product announcement list National Organization Drug Joint Procurement Office September 10, 2021 If this article violates your rights, please contact us .
-
Baiyunshan amoxicillin capsule passed the consistency evaluation
Time of Update: 2021-08-06
The amoxicillin capsule of Baiyunshan Pharmaceutical General Factory was officially launched in China in August 2006, and the consistency evaluation application was submitted to the National Medical Products Administration on November 4, 2018, and it was accepted on November 12, 2018 .
-
The regulation of retail pharmacies has changed
Time of Update: 2021-08-03
It is understood that through this platform, the regulatory authority controls retail drugstores containing ephedrine compound preparations and other drug business activities, such as assigning exclusive QR codes to pharmacies, and customers can collect ephedrine compound preparations when purchasing scan codes.
-
6 batches failed
Time of Update: 2021-05-31
005mg/L Drink Initial inspection agency: Zhumadian Food and Drug Inspection Institute; re-inspection agency: Henan Port Food Inspection and Testing Institute 6 Chongqing Caiyang Agricultural Development Cooperative Group 5, Taiping Community, Shima Town, Dazu District, Chongqing China Power Construction (Sanmenxia) Millennium Trading Co.
-
Chengdu Xiandao HG146 Capsule New Indication Clinical Trial Application Approved
Time of Update: 2021-05-10
HG146 (HDAC I / IIb subtype selective small molecule inhibitors) is a pilot structure developed Chengdu Ying, proprietary, selective class I and class IIb histone deacetylase (HDAC) inhibitor , On April 12, 2018, obtained the original clinical approval of the National Food and Drug Administration (approval number: 2018L02338, 2018L02339), and is currently conducting clinical research on multiple myeloma.
-
Keytruda, Opdivo and Tecentriq will be reviewed by the FDA advisory committee this week
Time of Update: 2021-05-09
S. Food and Drug Administration (FDA)’s accelerated approval pathway, the fate of the three cancer immunotherapies will be determined this week after confirming trials have failed.
In February of this year, AstraZeneca stopped using its checkpoint inhibitor Imfinizi to treat bladder cancer after announcing the failure of the confirmatory trial.
-
FDA approves first targeted treatment for rare Duxing muscular dystrophy
Time of Update: 2021-02-22
With today's accelerated approval, patients with Duxing, a rare and devastating disease, can skip Vyondys 53 if their muscular dystrophy protein gene is confirmed to have mutated, and will now receive the first treatment specifically for the disease subtype," the FDA said.
-
Jiangxi Provincial Drug Administration issued a notice: 15 varieties of 18 batches of sampling failed
Time of Update: 2021-01-31
The investigation and prosecution of non-compliant drugs The Jiangxi Provincial Drug Administration has tasked the relevant departments to take necessary control measures such as seizure, seizure, suspension of sales and recall of non-compliant drugs for inspection, and to investigate and punish the production enterprises and the sampling units in accordance with relevant laws and regulations.
